Boyle Scott N 4
4 · C4 Therapeutics, Inc. · Filed Nov 12, 2024
Insider Transaction Report
Form 4
Boyle Scott N
Chief Business Officer
Transactions
- Exercise/Conversion
Common Stock
2024-11-07+3,750→ 57,669 total - Tax Payment
Common Stock
2024-11-07$6.04/sh−1,102$6,656→ 56,567 total - Exercise/Conversion
Performance Restricted Stock Units
2024-11-07−3,750→ 10,500 totalExp: 2025-02-28→ Common Stock (3,750 underlying)
Footnotes (2)
- [F1]Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones.
- [F2]Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person.